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The in vitro culture of human peripheral blood lymphocytes in IL-2 results in
the generation of cytotoxic cells that lyse NK-resistant tumor cell targets without
MHC restriction . This has been referred to as the LAK (lymphokine-activated
killer)' phenomenon (1-3). There has been considerable controversy regarding
the types of effector cells mediating this activity, particularly concerning the
relative contribution of natural killer cells versus cytotoxic T cells. Grimm and
colleagues (1) have reported that the effectors of the LAK phenomenon express
the pan T cell antigens CD3 and CD5 . However, in subsequent studies (2), these
investigators characterized the precursor population as a lymphoid cell lacking
CD3 and CD5.
In contrast, we (4) and others (5, 6) have shown that CD3- NK cells that
express the CD 16 (Leu-11) antigen can lyse NK-resistant hematopoietic tumor
cell targets after culture in vitro with IL-2. These studies however, did not
exclude the possibility that a subset of CD3+ T lymphocytes may also contribute
to the LAK phenomenon. Here, we determine the relative contribution of NK
cells and T lymphocytes to the LAK phenomenon, examining both the precursor
and effector phase of this response .
Materials and Methods
Human Peripheral Blood Leukocytes.
￿
Human peripheral blood from normal, random
donors was obtained from the Stanford Blood Center, Palo Alto, CA. The mononuclear
cells were isolated using Ficoll/Hypaque . After passage through nylon wool (7), nonad-
herent lymphocytes were fractionated by centrifugation on discontinuous gradients con-
sisting of 30% and 40% Percoll (Pharmacia Fine Chemicals, Piscataway, NJ) in PBS
containing 10% FCS (7). Low bouyant density and high bouyant density lymphocytes
were isolated from the interface and bottom of the Percoll gradients, respectively. Total
cell recovery was -85% . ^-25% of lymphocytes were in the low bouyant density fraction,
depending on the individual donor. The population of lymphocytes in the interface
fraction were highly enriched for cellswith large granular lymphocyte (LGL) morphology.
Monoclonal Antibodies. Leu series mAbs were prepared at the Becton Dickinson
Monoclonal Center. The CD nomenclature of the differentiation antigens identified by
these mAbs is summarized in Table I. Anti-Leu-11 reacts with CD16, the Fc receptor for
IgG expressed on NK cells and neutrophils (9). Anti-Leu-19 reacts with the Leu-19 (NKH-
'Abbreviations used in this paper:
￿
LAK, lymphokine-activated killer; LGL, largegranular lympho-
cytes; PE, phycoerythrin.
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TABLE I
CD Nomenclaturefor Differentiation Antigens Identified by mAb Used
in This Study
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1) antigen, an ^-220 kD protein of unknown function expressed on NK cells and a subset
of T lymphocytes (10, 11).
Immunofuorescence and Flow Cytometry.
￿
Methods of immunofluorescence, flow cytom-
etry, and data analysis have been described (9, 12, 13). A FACS 440 flow cytometer and
Consort 40 data analysis system (Becton Dickinson Immunocytometry Systems, Mountain
View, CA) were used. Fluorochrome-conjugated, isotype-matched mAbs that do not react
with human leukocytes were used to control for nonspecific binding in the immunofluo-
rescence assays.
Cell Lines. All tumor cell lines were obtained from the American Type Culture
Collection, Rockville, MD and were tested monthly to ensure against mycoplasma infec-
tion. Freshly isolated human tumors were generously provided by Drs. Anthony Rayner
and Brett Gemlo (Department of Surgery, University of California Medical School, San
Francisco, CA).
Cytotoxicity Assays.
￿
"Cr-labeled tumor cells were used as targets in a 4-h radioisotope-
release assay (9).
Lymphocyte Activation.
￿
Lymphocytes (^-106 cells/ml) were cultured in RPMI-1640 (M.
A. Bioproducts, Walkersville, MD) containing 5% horse serum (JR Scientific, Woodland,
CA), 1 mM glutamine (Gibco Laboratories, Grand Island, NY), and 100 ug/ml gentamicin
(Gibco). rIL-2 (4) was added to the cultures at 1,000 U/ml. Preliminary studies established
that this concentration of rIL-2 induced optimal cytotoxicity, although lower concentra-
tions were sufficient to initiate the response.
Results and Discussion
Characterization ofEffector Cells.
￿
We recently showed that two distinct subsets
of peripheral blood lymphocytes can lyse NK-sensitive tumor targets without
deliberate immunization or MHC-restriction (10). These cytotoxic subsets were
identified by two-color immunofluorescence using antibodies against CD3, a
component of the T cell antigen receptor and the Leu-19 (NKH-1) antigen (10).
Both CD3-,Leu-19' NK cells and the CD3+,Leu-19+ T cells isolated directly
from peripheral blood mediated non-MHC restricted cytotoxicity (10). Within
the CD3',Leu-19+ T cell subset, most cells expressed the CD2, CD5, and CD8
differentiation regions, but did not express CD16 (10). In contrast, ^-90% of the
CD3-,Leu-19+ NK cell subset coexpressed CD16, and none expressed the pan
T cell antigen CD5 (10). The minor population of CD3 -,CD16-,Leu-19+ lym-
phocytes also mediated non-MHC restricted cytotoxicity, and were phenotypi-
cally identical to CD3-,CD16',Leu-19+ NK cells, with the exception of lacking
CD 16 expression (10).
In the present studies, we examined the relative contribution of CD3 -,Leu-
19+ NK cells (referred to as NK cells), CD3 +,Leu-19+ non-MHC restricted
CD cluster mAb Major cell reactivity
CD3 Leu-4 T cells (antigen receptor complex)
CD4 Leu-3 Tsubset and monocytes
CD5 Leu-1 Tcells and Bcell subset
CD8 Leu-2 Tsubset and NK subset
CD16 Leu-11 NK cellsand neutrophils (Fc receptor)
ND Leu-19 (NKH-1) NK cellsand T subset816
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FIGURE 1 .
￿
Coexpression of CD5 and Leu 19 on low bouyant density lymphocytes . Low
bouyant density lymphocytes were stained with FITC-conjugated anti-Leu-1 (CD5)and biotin-
conjugated anti-Leu-19, followed by PE-conjugated streptavidin . Cells were analyzed by flow
cytometry, and data were displayed as contour plots of FITC and PE fluorescence . The
contour map was divided into quadrants to represent : cells stained only with PE (upper left),
cells stained with FITC and PE (upper right), cells stained only with FITC (lower right) and
unstained cells (lower left) . In the control sample (cells stained with FITC- and PE-conjugated
IgG control antibodies), >98% of lymphocytes were in the lower right quadrant . In subsequent
figures, CD5-,Leu-19' lymphocytes are referred to as NK cells, CD5+,Leu-19' lymphocytes
are referred to as Leu-19'T cells, andCD5',Leu-19- lymphocytes are referred to as Leu-19-
T cells.
cytotoxic T cells (referred to as Leu-19+ T cells), and CD3',Leu-19- T cells
(referred to as Leu-19- T cells) to the LAK phenomenon . Prior studies (2)
indicated that precursors of the LAK phenomenon were low bouyant density
lymphocytes that comigrated, on Percoll gradients, with NK cells . Therefore,
low bouyant density lymphocytes (designated LGL) from normal peripheral
blood were cultured in medium containing rIL-2 . After 7 d, cells were harvested
and stained with FITC-conjugated anti-Leu-1 (CD5) and biotin-conjugated anti-
Leu-19, followed by PE (phycoerythrin)-conjugated streptavidin (Fig . 1) . Anti-
CD5 was used to identify and isolate T cells, since antibodies against CD3 have
been shown to either inhibit or induce T cell-mediated cytotoxicity (14-16) . NK
cells (CD5-,Leu-19+ , comprising 55% of total low bouyant density lymphocytes),
Leu-19+ T cells (CD5+,Leu-19+, 24%), and Leu-19- T cells (CD5+,Leu-19- ,
14%) were isolated by cell sorting using a FACS . Reanalysis indicated >95%
purity in all populations . These rIL-2 activated cells were then tested for
cytotoxicity against the NK-sensitive tumor cell line, K562, as well as an NK-
resistant colon carcinoma cell line (COLO) (Fig . 2B) . Both the rIL-2-activated
NK cells and Leu-19+ T cells lysed K562 . However, significant lysis of the solid
tumor cell line was predominately mediated by rIL-2-activated NK cells . rIL-2-
activated Leu-19+ T cells showed only minimal cytotoxic activity against COLO,
while Leu-19- T cells totally lacked cytotoxic function against either K562 or
COLO (Fig . 2B) . For comparison, we also isolated NK cells, Leu-19+ T cells,
and Leu-19- T cells from the low bouyant density lymphocytes population, and
tested these freshly isolated cells for cytotoxicity before culture in rIL-2 . As
shown in Fig . 2A, freshly isolated NK cells efficiently lysed K562, but did not
lyseCOLO . Freshly isolated Leu-19+ T cells mediated low levels of cytotoxicity
against K562, but not COLO . Leu-19- T cells were not cytotoxic . EssentiallyPHILLIPS AND LANIER
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FIGURE 2.
￿
Cytotoxicity mediated by rIL-2-cultured lowbouyant density lymphocyte subsets.
A: Freshly isolated low bouyantdensity lymphocytes (LGL; O), Leu-19+ T cells (,L), Leu-19-
T cells(0), and NK cells (p)were assayed for cytotoxic activity against K562 (left) and COLO
(right) before culture. B:Lowbouyantdensity lymphocytes were cultured in medium containing
rIL-2 for 7 d. Lymphocytes were harvested and stained with mAbs, as described in Fig. 1.
rIL-2-activated Leu-19+ T cells, Leu 19- T cells, and NK cellswere isolated using the FACS
and tested for cytotoxicity against K562 (left) and COLO (right).
identical results were obtained with lymphocytes isolated from three different
blood donors.
Cytotoxicity against freshly isolated human tumors was also mediated exclu-
sively by IL-2-activated NK cells, as shown in Fig. 3. In these experiments, low
bouyantdensity lymphocytes were cultured in rIL-2, and the NK cell (CD5-,Leu-
19+) and T cell (CD5+,Leu-19+ and CD5+,Leu-19-) subsets were isolated using
the FACS. rIL-2-activated NK cells and T cells were assayed for cytotoxicity
against K562, the colon carcinoma cell line (COLO), freshly isolated melanoma
tumor cells, freshly isolated Wilms' tumor cells, and freshly isolated sarcoma
tumor cells. Freshly isolated tumors, as well as the COLO cell line, were efficiently
killed by rIL-2-activated NK cells, but not rIL-2-cultured T cells(Fig. 3). As seen
previously, rIL-2-cultured T cells mediated low levels of cytotoxicity against
K562. It should be noted that the magnitude of cytotoxicity against the three
freshly isolated tumors was equivalent to the activity observed against COLO.
COLO and the freshly isolated tumor cells were completely resistant to lysis
mediated by unactivated peripheral blood NK cells (not shown) . Since cytotox-
icity against COLO and the fresh tumor cells was equivalent, COLO was used
for most subsequent experiments.
To exclude the possibility that Percoll fractionation biased these results,
unseparated peripheral blood mononuclear cells were also cultured in rIL-2.
After 7 d of culture, cells were stained with FITC-conjugated anti-Leu I (CD5)818
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FIGURE 3 .
￿
Cytotoxicity against freshly isolated tumor cells mediated by low bouyant density
lymphocyte subsets . Low bouyant density lymphocytes were cultured in medium containing
rIL-2 for 7 d . Lymphocytes were harvested and stained with mAbs, as described in Fig . 1 .
rIL-2-activated unsorted cells (A), CD5-,Leu-19' NK cells (B), andT cells (pool of CD5',Leu-
19- and CD5',Leu-19') (C) were tested for cytotoxicity against K562 (A), COLO (O), a fresh
melanoma tumor (/), fresh sarcoma tumor ([I), and fresh Wilms' tumor (6) .
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FIGURE 4.
￿
Cytotoxicity mediated by rIL-2-cultured peripheral blood mononuclear cell sub-
sets . Peripheral blood mononuclear cells (O) isolated from Ficoll/Hypaque gradients were
cultured in medium containing rIL-2 for 7 d. Lymphocytes were harvestedand stained with
mAbs, as described in Fig. 1 . Leu-19' T cells (A) and NK cells (O) were isolated using the
FACS and tested for cytotoxicity against K562 (left) and COLO (right) .
E/T
PBL- 1 wk rIL-2
and biotin-anti-Leu-19, followed by PE-conjugated streptavidin . Leu-19+T cells
(comprising 21% of total lymphocytes), Leu-19- T cells (66%), and NK cells (8%)
were isolated to >95% purity using the FACS . Again, lysis of the NK-insensitive
colon cell line, COLO, was predominately mediated by rIL-2-activated NK cells
(Fig . 4) . Although peripheral blood rIL-2-activated Leu-19+ T cells showed low
levels of killing against K562, these T cells did not substantially contribute to
the lysis ofCOLO . Again, Leu-19- T cells killed neither K562 nor COLO .
Characterization of Precursor Cells.
￿
Low bouyant density peripheral blood
lymphocytes, enriched on Percoll gradients, were stained with FITC-conjugated
anti-Leu 1 (CD5) and biotin-conjugated anti-Leu-19, followed by PE-streptavidin .
Leu-19' T cells, Leu-19- T cells, and NK cells were isolated to >95% purity
using the FACS, and were placed in culture in medium containing HL-2 . After
7 d, lymphocytes were harvested and examined for antigenic phenotype and
cytotoxic function . After culture in HL-2, >95% of the Leu-19' T lymphocytes
retained the phenotype CD3 +,CD5+,Leu-19+ . Likewise, Leu-19- T lymphocytesU x 0
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FIGURE 5. Precursors of rIL-2-activated cytotoxic cells. A: Freshly isolated low bouyant
density lymphocytes (O) were stained with mAbs, as described in Fig. 1. Leu-19' T cells (A),
Leu-19- T cells (")and NK cells (p) were isolated using the FACS and assayed immediately
forcytotoxicactivity against K562 (left) and COLO (right). B: Leu-19' Tcells, Leu-19- Tcells
and NK cells were isolated using the FACS and placed in culture with rIL-2. After 7 d, cells
were harvestedand assayed forcytotoxicity against K562 (left) andCOLO (right).
remained CD3+,CD5+,Leu-19-. >95%D of rIL-2-cultured NK cells maintained
the phenotype CD3-,CD5-,Leu-19+, and as observed before culture, ^-90%
expressed the CD 16 antigen. There was no evidence that NK cells ever acquired
pan T cell antigens as a consequence of culture in rIL-2 or that T cells lost CD3
expression after culture.
The cytotoxic activity of these subsets was tested before culture (Fig. 5A) or
after culture in rIL-2 for 7 d (Fig. 5B). Again, the rIL-2-cultured NK cells were
potent mediators of lysis against both K562 and COLO ; whereas the freshly
isolated NK cells lysed K562, but not COLO (Fig. 5). In contrast, freshly isolated
and rIL-2-activated Leu-19' T cells lysed K562, but showed only minimal
cytotoxicity against COLO. In this individual, culture in rIL-2 did not signifi-
cantly augment the cytotoxicity of Leu-19' T cells against K562; however, in
several other individuals (e.g., Figs. 6 and 8), we did observe rIL-2-enhanced
cytotoxicity against K562, but not COLO. Non-MHC restricted cytotoxic lym-
phocytes were not generated by culture of Leu-19- T cells in rIL-2.
To further examine the cytotoxic potential of these cells, NK cells and Leu-
19+ T cells were isolated from the low bouyant density lymphocyte population,
were cultured for 1 wk in rIL-2, and were then assayed for cytolytic activity
against K562, COLO, ZR (an NK-resistant breast carcinoma cell line), and JY
(an NK-resistant B lymphoblastoid cell line) (Fig. 6). Freshly isolated NK cells
and Leu-19' T cells lysed K562, although NK cells were more effective effectors.
Against the hematopoietic cell targets (K562 and JY), rIL-2 enhanced the
cytotoxicity of both the NK cells and Leu-19+ T cells. In contrast, only the NK820
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FIGURE 6 .
￿
Cytotoxicity mediated by rIL-2 activated NK cells and Leu-19+T cells. NK cells
(A) and Leu-19+T cells (B) were isolated using the FAGS andplaced in culture with rIL-2 for
7 d . Freshly isolated cells and rIL-2-activated cells were assayed for cytotoxicity against K562,
JY, COLO, and ZR . E/T ratio is 12 :1 .
cells showed substantial rIL-2-induced cytotoxicity against the solid tumor cell
lines . These results unequivocally demonstrate that HL-2 provides the only signal
necessary for NK cells to lyse solid tumor cell targets . T cells, accessory cells, or
additional factors are apparently not required . Furthermore, these studies show
that NK cells with the ability to efficiently lyse NK-insensitive solid tumor cell
targets arise from a precursor population with the phenotype CD5-,Leu-19+.
More extensive immunophenotyping has shown that -90% of these precursor
cells coexpress CD16, and all lack CD3 . We have recently reported that this
CD3-,CD16+ NK cell population does not rearrange T cell antigen receptor ,0
genes (17), suggesting that NK cells are distinct in origin from the T cell lineage
and do not use the T cell antigen receptor for target recognition .
Within the CD3-,Leu-19+ NK cell subset, ^-10% of these cells lack expression
ofCD16 . Freshly isolated CD3-,CD16-,Leu-19+ lymphocytes killed NK-sensitive
tumor cell targets, but not NK-insensitive targets (10) . To determine whether
this population responds to HL-2, low bouyant density lymphocytes were stained
with a combination of FITC-conjugated anti-Leu-4 (CD3), FITC-conjugated
anti-Leu-11 (CD16), and biotin-conjugated anti-Leu-19, followed by PE-conju-
gated streptavidin . Lymphocytes displaying only red (PE) immunofluorescence
would therefore possess the phenotype CD3-,CD16-,Leu-19+ (10) . This small
population (<5% of peripheral blood, low bouyant density lymphocytes) was
isolated to >95% purity using the FAGS, and cultured in medium containing
HL-2 for 24 h, 1 wk, and 4wk (Fig. 7) . After HL-2 activation, CD3-,CD16-,Leu-
19+ cells lysed both K562 and COLO (Fig . 7) . Reexamination of the antigenic
phenotype indicated that >95% of the cells remained CD3-,CD16-,Leu-19+.
These findings show that a small subset ofLeu-19+ lymphocytes, lacking expres-
sion of both the CD3 and CD16 antigens can respond to HL-2 and lyse both
K562 andCOLO . The relationship of these CD3-,CD16-,Leu-19+ lymphocytes
to CD3-,CD16+,Leu-19+ NK cells is unknown, although we have suggested thatPHILLIPS AND LANIER
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FIGURE 7. Cytotoxicity mediated by rIL-2-activated CD3-,CD16-,Leu-19+ cells. Freshly
isolated low bouyant density lymphocytes were stained with mAbs, as described in the text.
CD3-,CD16-,Leu-19+ lymphocytes were isolated using the FACS and placed in culture with
rIL-2 for 24 h (p), 1 wk (A), and 4 wk ("). Freshly isolated (Q)and rIL-2-activated cells were
assayed forcytotoxicity against K562 (A) and COLO (B).
this population may represent the stage of NK cell differentiation before acqui-
sition of CD16 Fc receptors (10).
Kinetics of the Response.
￿
Leu 19+ Tcells and NK cells were isolated from the
low bouyant density lymphocyte population using the FACS, and cultured in
medium containing rIL-2. Cells were harvested after 18 h and after 1 wk, then
assayed for cytotoxicity against K562 and COLO. As shown in Fig. 8, killing of
K562 was substantially enhanced in both the Leu-19+ T cell and NK cell
populations within 18 h. Maximal lysis ofCOLO by NK cells was also detectable
after 18 h, and did not significantly increase upon longer culture. Leu-19+ T
cells mediated only minimal lysis against the solid tumor cell target at all time
points examined.
Conclusions.
￿
These studies show that the LAK phenomenon is predominately
mediated by rIL-2-activated NK cells. Both the precursor and effector of this
activity were typical NK cells, with the phenotype CD3-,Leu-19+. There was no
evidence for a unique LAK cell. Moreover, rIL-2 apparently provided the only
signal necessary for NK cells to lyse fresh solid tumor cell targets; there was no
evidence that accessory cells or T lymphocytes were required to generate this
response. The mechanism whereby NK cells become competent to recognize and
lyse solid tumor cell targets after brief exposure to rIL-2 is not understood.
Overall, peripheral blood Tlymphocytes contributed little to the LAK phenom-
enon. However, these Leu-19+ T cells lysed hematopoietic targets without
deliberate immunization or MHC restriction, and their cytotoxicity was usually
significantly augmented by rIL-2. We are examining whether or not these Leu-
19+ T cells preferentially recognize antigens expressed on hematopoietic cells,
and not other tissues. We observed that Leu-19+ T cells apparently proliferated
more rapidly in response to rIL-2 than did NK cells (unpublished observation).
The practical implications of this finding are that long term culture of unsepa-
rated low bouyant density peripheral blood lymphocytes in IL-2 results predom-822
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FIGURE 8. Kinetics of rIL-2-activated cytotoxicity. Freshly isolated low bouyant density
lymphocytes (0) were stained with mAbs, as described in Fig. 1. Leu-19+T cells (A) and NK
cells (Q) were isolated using the FACS,and placed in culture with HL-2.At the indicatedtime
points (A, freshly isolated; B, 18 h; C 1 wk), cells were harvested and assayed for cytotoxicity
against K562 (left) and COLO (right).
inately in T cell growth, with a relative loss of NK cells. If the primary objective
is to optimize generation of effectors mediating solid tumor cell cytotoxicity, this
differential growth rate should be taken into account.
The present studies conflict with earlier reports (1-3) on the LAK phenome-
non. The most notable discrepancy is that these investigators suggested that
LAK was mediated partially by a CD3+ T cell population (1-3). Recently, we
have shown that a subset of low bouyant density peripheral blood T lymphocytes
can lyse NK-resistant targets in the presence, but not in the absence, of mitogenic
lectins (16). In these early studies of the LAK effector, lectin-containing super-
natant was used as the source of IL-2 (1, 2) . Perhaps the T cell-mediated
cytotoxicity in these prior studies was actually lectin-dependent cellular cytotox-
icity. We have also shown that maximal cytotoxicity is achieved within 18 h after
exposure of NK cells to rIL-2. Earlier studies (1) suggested that this process
required 3 d. Again, we believe that this difference in kinetics is due to the
preparations of IL-2 used in the experiments. In the previous studies, the
concentration of IL-2 used to generate LAK activity was G5 U/ml (3). We andPHILLIPS AND LANIER
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others (4, 5) have since determined that optimal generation of cytotoxicity
requires >500 U/ml. Since the concentration of IL-2 is the rate-limiting factor
in the induction of cytotoxicity, it seems quite likely that under suboptimal
conditions that the generation of cytotoxicity would require a longer time. In
accordance with the studies by Grimm et al. (2), our data confirm that the
precursor of the LAK effector is a CD3- lymphocyte, and is in fact an NK cell.
The results from this study only apply to the LAK phenomenon using lympho-
cytes obtained from peripheral blood. Clearly, non-MHC restricted cytotoxic
lymphocytes can be generated from lymphoid tissues devoid of NK cells, such as
lymph nodes and thymus (2, 18). We have recently shown (unpublished obser-
vation) that culture of human thymocytes, but not peripheral blood T cells, in
rIL-2 results in the generation of Leu-19+,CD3+ T lymphocytes that lyse solid
tumor cell lines without MHC-restriction. Comparison ofthe thymic Leu-19+ T
cells and peripheral blood Leu-19' T cells is under investigation. These findings
caution against direct extrapolation of results using animal models of the LAK
phenomenon, where the effector cell populations are derived from the spleen,
thymus, or lymph node, and not peripheral blood. It is important to remember
that LAK is an activity, not a unique, homogeneous cell type. In blood, the
effector ofLAK is clearly an NK cells, whereas in other lymphoid tissues such as
thymus, the effectors of LAK are probably CD3+ T cells. Since peripheral blood
has been the source for immunotherapeutic use ofrIL-2-activated cytotoxic cells
in cancer patients (19), our studies suggest that rIL-2-activated NK cells are
probably the effectors in this situation.
Summary
In vitro culture of human peripheral blood lymphocytes in IL-2 results in the
generation ofcytotoxic cells that can lyse fresh and cultured solid tumor cells, as
well as hematopoietic tumor cell lines, without deliberate immunization or MHC
restriction. This has been referred to as the lymphokine activated killer (LAK)
phenomenon . Here, we show that the majority ofthis activity is mediated by NK
cells that express the Leu-19 (NKH-1) antigen, but do not express CD3. The
precursor of this effector population also expressed the phenotype CD3-,Leu-
19+. Peripheral blood CD3+ T lymphocytes contributed little to the LAK
phenomenon, although low levels of non-MHC restricted cytotoxicity against
hematopoietic tumor cell targets were mediated by a subset ofCD3+ T lympho-
cytes that coexpressed the Leu-19 antigen. These studies clearly indicated that
the LAK phenomenon is not mediated by a unique LAK cell, but is mediated
mainly by IL-2-activated peripheral blood NK cells.
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